Importantly, we found that HCC cells exhibit a high degree of sensitivity to the selective AXL inhibitor BGB324, independent of AXL expression levels, and combining siCAV1 or BGB324 with sorafenib resulted in a significant reduction in the growth of HCC cells and PDOs. The gene discussed is AXL; the disease is hepatocellular carcinoma.